Perfluten
Phase 2Small molecule
Perfluten is one of 16 small molecule programs targeting Uterine Fibroid. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Uterine Fibroid
#DrugCompanyPhaseTrials
1Orilissa
AbbVieApproved
Femara
NovartisApproved
Lupron
Sun Pharmaceutical Industries, Inc.Approved
Cytotec
PfizerApproved
Mifeprex
DDanco
Approved
Cyklokapron
JJ Molner
Approved
Zoladex
TTerSera Therapeutics LLC
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Esbriet
LLegacy Health System
Approved
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Perfluten. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TThomas Jefferson University